A new study of Cephalon's Trisenox for acute promyelocytic leukemia demonstrated increased survival time. "The results of this study showing a survival benefit associated with the use of Trisenox ...

European regulators have expanded the scope of Teva Pharmaceutical's Trisenox, approving its use to treat patients with newly diagnosed Acute Promyelocytic Leukaemia (APL), a rare and aggressive type ...

Cell Therapeutics, Inc. (CTI) Completes Transaction Divesting TRISENOX(R) to Cephalon, Inc. SEATTLE, July 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI ...